T2 Biosystems (NASDAQ:TTOO) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of T2 Biosystems (NASDAQ:TTOO) in a research report sent to investors on Tuesday. The firm issued a sell rating on the medical equipment provider’s stock.

T2 Biosystems Trading Down 11.6 %

Shares of TTOO opened at $0.23 on Tuesday. The business’s fifty day moving average is $0.42 and its 200 day moving average is $2.04. T2 Biosystems has a 12-month low of $0.23 and a 12-month high of $6.95.

Hedge Funds Weigh In On T2 Biosystems

An institutional investor recently bought a new position in T2 Biosystems stock. Armistice Capital LLC acquired a new stake in shares of T2 Biosystems, Inc. (NASDAQ:TTOO) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 1,658,000 shares of the medical equipment provider’s stock, valued at approximately $8,854,000. Armistice Capital LLC owned approximately 9.49% of T2 Biosystems at the end of the most recent quarter. Institutional investors own 23.18% of the company’s stock.

T2 Biosystems Company Profile

T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.